Clinical Cancer Research, Vol 3, Issue 10 1867-1872, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Allelic loss on chromosome 13q in human prostate carcinoma

J Melamed, JM Einhorn and MM Ittmann
Department of Pathology, New York University School of Medicine, Kaplan Cancer Center, New York, New York 10010, USA.

To clarify the role in prostate tumorigenesis played by loss of the three known or putative tumor suppressor loci on the centromeric portion of chromosome 13q, we examined 80 clinically localized and 15 advanced prostate carcinomas for allelic loss at microsatellite markers mapped to this region, including markers tightly linked to the BRCA-2, retinoblastoma (Rb), and DBM (deleted in B-cell malignancy) loci. Among the 80 clinically localized cases, 24 showed allelic loss at one or more 13q loci. In all cases with loss, the Rb and/or DBM loci were lost. No cases were found with loss of Rb without loss of DBM or loss of DBM without loss of Rb, implying a role for both the Rb and DBM loci in clinically localized prostate cancer. Loss of the BRCA-2 locus was less common (4 of 55 informative cases) and was always associated with loss of Rb and/or DBM loci. Thus, the BRCA-2 locus does not appear to play as important a role in clinically localized prostate cancer as the Rb and/or DBM loci. Allelic loss on 13q was extremely common in the clinically advanced cases; it was present in 14 of the 15 cases. The rate of allelic loss at each of the three tumor suppressor loci was increased significantly in the advanced cases (P < 0.01, Fisher's exact test). Thus, loss of heterozygosity on 13q is very common in prostate cancer and occurs at all three known or putative tumor suppressor loci on the centromeric portion of chromosome 13q.

This article has been cited by other articles:

				A. J. Willems, S.-J. Dawson, H. Samaratunga, A. De Luca, Y. C. Antill, J. L. Hopper, H. J. Thorne, and and kConFab Investigators Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation Clin. Cancer Res., May 15, 2008; 14(10): 2953 - 2961. [Abstract] [Full Text] [PDF]

				R. Hill, Y. Song, R. D. Cardiff, and T. Van Dyke Heterogeneous Tumor Evolution Initiated by Loss of pRb Function in a Preclinical Prostate Cancer Model Cancer Res., November 15, 2005; 65(22): 10243 - 10254. [Abstract] [Full Text] [PDF]

				N. Chunder, S. Mandal, A. Roy, S. Roychoudhury, and C. K. Panda Differential Association of BRCA1 and BRCA2 Genes with Some Breast Cancer-Associated Genes in Early and Late Onset Breast Tumors Ann. Surg. Oncol., December 1, 2004; 11(12): 1045 - 1055. [Abstract] [Full Text] [PDF]

				L. A. Maddison, B. W. Sutherland, R. J. Barrios, and N. M. Greenberg Conditional Deletion of Rb Causes Early Stage Prostate Cancer Cancer Res., September 1, 2004; 64(17): 6018 - 6025. [Abstract] [Full Text] [PDF]

				S Dasgupta, S B Chakraborty, A Roy, S Roychowdhury, and C K Panda Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients Mol. Pathol., October 1, 2003; 56(5): 263 - 269. [Abstract] [Full Text] [PDF]

				T Ikonen, M P Matikainen, K Syrjakoski, N Mononen, P A Koivisto, A Rokman, E H Seppala, O-P Kallioniemi, T L J Tammela, and J Schleutker BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland J. Med. Genet., August 1, 2003; 40(8): e98 - 98. [Full Text] [PDF]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				M. Marcelli, M. Ittmann, S. Mariani, R. Sutherland, R. Nigam, L. Murthy, Y. Zhao, D. DiConcini, E. Puxeddu, A. Esen, et al. Androgen Receptor Mutations in Prostate Cancer Cancer Res., February 1, 2000; 60(4): 944 - 949. [Abstract] [Full Text]

				D. J. Simpson, J. Magnay, J. E. Bicknell, A. L. Barkan, A. M. McNicol, R. N. Clayton, and W. E. Farrell Chromosome 13q Deletion Mapping in Pituitary Tumors: Infrequent Loss of the Retinoblastoma Susceptibility Gene (RB1) Locus Despite Loss of RB1 Protein Product in Somatotrophinomas Cancer Res., April 1, 1999; 59(7): 1562 - 1566. [Abstract] [Full Text] [PDF]